糖化血红蛋白升高与减重手术并发症的关系
该回顾性研究基于MBSAQIP数据库2017-2018年118,742例腹腔镜袖状胃切除术和Roux-en-Y胃旁路术患者,评估术前HbA1c与30天并发症复合结局的关系。倾向性评分匹配后,HbA1c>8%或>10%与并发症增加无关;HbA1c≤10%的患者反而有更多复合并发症。
要点
- HbA1c>8%与≤8%相比,30天并发症复合结局无显著差异(p=0.22)。
- HbA1c≤10%的患者比>10%的患者有更多复合并发症(p<0.001)。
- 袖状胃和旁路亚组分析中,HbA1c>8%未加重复合结局(p=0.58和0.89)。
核心结论
- HbA1c>8%或>10%与减重术后并发症增加无关。
- HbA1c低于10%与部分不良结局相关。
- 仅HbA1c高可能不应作为减重手术的禁忌。
研究设计与样本
- 回顾性研究,数据来自MBSAQIP数据库2017-2018年。
- 纳入118,742例腹腔镜袖状胃切除术和腹腔镜Roux-en-Y胃旁路术患者。
- 采用倾向性评分匹配(1:1)比较HbA1c≤8% vs >8%和≤10% vs >10%。
主要发现
- 匹配后,HbA1c≤8% vs >8%的复合结局无统计学显著差异(p=0.22)。
- HbA1c≤10% vs >10%:≤10%组复合并发症更多(p<0.001)。
- 袖状胃亚组:HbA1c>8% vs ≤8%复合结局p=0.58,>10% vs ≤10% p=0.001。
- 胃旁路亚组:HbA1c>8% vs ≤8%复合结局p=0.89,>10% vs ≤10% p=0.007。
临床怎么用
- 高HbA1c本身可能不构成减重手术的排除标准。
- 需进一步研究以探讨HbA1c与减重手术结局的关系。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In cardiac and orthopedic surgery, elevated glycosylated hemoglobin (HbA1c) is a modifiable risk factor for postoperative complications. However, in bariatric surgery, there is insufficient evidence to assess the effectiveness of preoperative HbA1c assessment and its association with postoperative complications. The objective of this study was to assess the impact of HbA1c on early postoperative outcomes in bariatric surgery patients. METHODS: Patients who underwent laparoscopic sleeve gastrectomy and laparoscopic Roux-En-Y Gastric Bypass between 2017 and 2018 were selected for a retrospective review from the metabolic and bariatric surgery accreditation and quality improvement program (MBSAQIP) database. The study population of 118,742 patients was analyzed for our primary outcome which was defined as a composite of any postoperative complications occurring within 30 days. Two groups were defined by HbA1c cutoff: comparison point A (≤ 8% vs > 8%) and comparison point B (≤ 10% vs > 10%). Procedure-related complications were also examined on subgroup analysis. Propensity score matching (PSM) was used with one-to-one matching. The complication rates before and after PSM were calculated and assessed by Fisher's exact test and conditional logistic regression, respectively. RESULTS: After PSM, demographic and clinical characteristics were all balanced and elevated HbA1C was not associated with worse outcomes. After adjusting for underlying comorbidities, there was no statistically significant difference seen in the composite outcome for comparison point A HbA1C ≤ 8 and HbA1C > 8 (p = 0.22). For comparison point B, patients with HbA1C ≤ 10 had more composite complications compared to patients with HbA1C > 10 (p < 0.001). Also, on subgroup analysis after PSM for procedure-specific complications, patients above the cutoff threshold of 8 did not have worsened composite outcomes (p = 0.58 and 0.89 for sleeve and bypass, respectively). Again, at cutoff threshold of 10, patients in HbA1C ≤ 10 had more composite complications (p = 0.001 and 0.007 for sleeve and bypass, respectively). CONCLUSION: In this study of bariatric patients, elevated HbA1c > 8% or 10% was not associated with increased postoperative complications. HbA1c lower than 10% was associated with some types of adverse outcomes in this bariatric dataset. More studies are needed to investigate these findings further. A high HbA1c alone may not disqualify a patient from proceeding with bariatric surgery.
引用
- Nwokedi U, Zia M, Xu J, et al. Elevated hemoglobin A1c level and bariatric surgery complications. Surg Endosc. 2022. PMID: 35075523. doi:10.1007/s00464-022-09030-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。